References
- Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: Translating science into practice. Clin Pharmacol Ther 2012; 92: 467-75. 10.1038/clpt.2012.12022948889
- Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338: 499-505. 10.1056/NEJM1998021933808039468466
- Murphy SB, Fairclough DL, Hutchison RE, Berard CW. Non-Hodgkin’s lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989; 7: 186-93. 10.1200/JCO.1989.7.2.186
- Anderson JR, Jenkin RD, Wilson JF Kjeldsberg CR, Sposto R, Chilcote RR, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 1993; 11: 1024-32. 10.1200/JCO.1993.11.6.10248501488
- Shaw GM, Lammer EJ, Zhu HP, Baker MW, Neri E, Finnell RH. Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet 2002; 108: 1-6.10.1002/ajmg.1019511857541
- Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006; 9: 227-46. 10.1016/j.drup.2006.09.00117092765
- Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res 2001; 61: 7225-32.11585759
- The Pharmacogenomics Knowledgebase. Pharmacogenomics. Knowledge. Implementation. [citated 2017 Feb 06]. Available from: www.pharmgkb.org
- Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100: 3832-4. 10.1182/blood.V100.10.383212411325
- Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007; 52: 166-71. 10.1007/s10038-006-0096-z17180579
- Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21: 3084-91. 10.1200/JCO.2003.07.05612915598
- Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006; 28: 64-8. 10.1097/01.mph.0000198269.61948.9016462575
- Faganel Kotnik B, Dolzan V, Grabnar I, Jazbec J. Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2010; 51: 724-6. 10.3109/1042819100361140220141435
- Shimasaki N, Mori T, Torii C, Sato R, Shimada H, Tanigawara Y, et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2008; 30: 347-52. 10.1097/MPH.0b013e318165b25d18458567
- Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolžan V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011; 67: 993-1006. 10.1007/s00228-011-1046-z21509569
- Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 1798-800. 10.1038/leu.2008.6618368069
- Zgheib NK, Akra-Ismail M, Aridi C, Mahfouz R, Abboud MR, Solh H, et al. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics 2014; 24: 387-96. 10.1097/FPC.000000000000006925007187
- Iparraguirre L, Gutierrez-Camino A, Umerez M, Martin-Guerrero I, Astigarraga I, Navajas A, et al. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. Pharmacogenet Genomics 2016; 26: 517-25. 10.1097/FPC.000000000000024527649261
- Lopez-Lopez E, Ballesteros J, Piñan MA, Sanchez de Toledo J, Garcia de Andoin N, Garcia-Miguel P, et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics 2013; 23: 53-61. 10.1097/FPC.0b013e32835c3b2423222202
- Ribas G, González-Neira A, Salas A, Milne RL, Vega A, Carracedo B, et al. Evaluating HapMap SNP data transferability in a large-scale genotyping project involving 175 cancer-associated genes. Hum Genet 2006; 118: 669-79. 10.1007/s00439-005-0094-9
- Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001; 29: 233-7. 10.1038/ng1001-23311586306
- World Health Organization. Handbook for reporting results of cancer treatment. Geneva: 1979. p. 15-22.
- National Cancer Institute. Common Toxicity Criteria Version 1. [citated 2017 Feb 06]. Available from: URL: http://ctep.cancer.gov/reporting/ctc.html
- Broad Institute. HaploView software version 4.1. [citated 2017 Feb 06]. Available from: http://www.broad.mit.edu/haploview/haploview-downloads
- LGC. Science for a safer world. [citated 2017 Feb 06]. Available from: http://www.kbioscience.co.uk
- Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 17; 96: 434-42.
- Moscow JA, Gong M, He R, Sgagias MK, Dixon KH, Anzick SL, et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995; 55: 3790-4.7641195
- Whetstine JR, Gifford AJ, Witt T, Liu XY, Flatley RM, Norris M et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 2001; 7: 3416-22.11705857
- Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B, et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005; 65: 2482-7. 10.1158/0008-5472.CAN-04-260615781665
- Kałuzna E, Strauss E, Zając-Spychała O, Gowin E, Świątek-Kościelna B, Nowak J, et al. Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia. Eur J Pharmacol 2015; 769: 93-9. 10.1016/j.ejphar.2015.10.05826528799
- Liao QC, Li XL, Liu ST, Zhang Y, Li TY, Qiu JC. [Association between the methylenetetrahydrofolate reductase gene polymorphisms and haplotype with toxicity response of high dose methotrexate chemotherapy]. [Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2012; 33: 735-9.22968027
- Meza-Espinoza JP, Peralta-Leal V, Gutierrez-Angulo M, Macias-Gomez N, Ayala-Madrigal ML, Barros-Nuñez P, et al. XRCC1 polymorphisms and haplotypes in Mexican patients with acute lymphoblastic leukemia. Genet Mol Res 2009; 8: 1451-8. 10.4238/vol8-4gmr68720013659
- Chokkalingam AP, Bartley K, Wiemels JL, Metayer C, Barcellos LF, Hansen HM, et al. Haplotypes of DNA repair and cell cycle control genes, X-ray exposure, and risk of childhood acute lymphoblastic leukemia. Cancer Causes Control 2011; 22: 1721-30. 10.1007/s10552-011-9848-y21987080
- Mosor M, Ziółkowska I, Januszkiewicz-Lewandowska D, Nowak J. Polymorphisms and haplotypes of the NBS1 gene in childhood acute leukaemia. Eur J Cancer 2008; 44: 2226-32. 10.1016/j.ejca.2008.06.02618691878
- Semsei AF, Erdélyi DJ, Ungvári I, Kámory E, Csókay B, Andrikovics H, et al. Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res 2008; 32: 1214-20. 10.1016/j.leukres.2007.12.00918243305
- Pakakasama S, Sirirat T, Kanchanachumpol S, Udomsubpayakul U, Mahasirimongkol S, Kitpoka P, et al. Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer 2007; 48: 16-20. 10.1002/pbc.2074216435384
- Bohanec Grabar P, Leandro-García LJ, Inglada-Pérez L, Logar D, Rodríguez-Antona C, Dolžan V. Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients. Pharmacogenomics 2012; 13: 1583-94. 10.2217/pgs.12.15023148635
- Lima A, Bernardes M, Azevedo R, Monteiro J, Sousa H, Medeiros R, Seabra V. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci 2014; 142: 196-209. 10.1093/toxsci/kfu16225124723
- Williams FM, Flintoff WF. Structural organization of the human reduced folate carrier gene: evidence for 5’ heterogeneity in lymphoblast mRNA. Somat Cell Mol Genet 1998; 24: 143-56.10.1023/B:SCAM.0000007117.50428.6310226652
- Whetstine JR, Flatley RM, Matherly LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J 2002; 367: 629-40. 10.1042/BJ2002051212144527
- Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009; 27: 5972-8. 10.1200/JCO.2008.20.4156
- Vidan-Jeras B, Jurca B, Dolzan V, Jeras M, Breskvar K, Bohinjec M. Caucasian Slovenian normal. In: Gjertson DW, Terasaki PI, editors. HLA 1998. Lenexa: American society for histocompability and immunogenetics; 1998. p. 180-1.